David B. Rawlins

Dr. David B. Rawlins serves as Associate Professor at Roseman University of Health Sciences, College of Pharmacy in Henderson, NV. With over two decades of pharmaceutical industry experience, he brings extensive expertise in drug discovery to his academic role. His academic appointments include memberships in the American Chemical Society (since 1989), American Association of Colleges of Pharmacy (since 2016), and American Association of Pharmaceutical Scientists (since 2016).

• Ph.D. in Chemistry from Stanford University (1990-1995)
• M.S. in Chemistry from Brigham Young University (1988-1990)
• B.S. in Microbiology from Brigham Young University (1982-1988)

Dr. Rawlins' research focuses on medicinal chemistry with particular emphasis on developing novel therapeutics. His work spans multiple therapeutic areas including antidepressant development through chemical synthesis of Ro-25-6981 analogs, investigation of essential oils' composition and biological activity, and innovative drug delivery methods using 3D printing technology. His industry background in oncology, metabolic disease, and ophthalmology drug discovery informs his current academic research directions. He has also developed informatics tools for tracking student information within the College of Pharmacy, bridging his cheminformatics expertise with educational applications.

Analysis of Dr. Rawlins' publication record reveals strong expertise in diabetes therapeutics (particularly SGLT inhibitors), ophthalmic treatments (including glaucoma), and antidepressant development. His work demonstrates a consistent pattern of translating basic chemical research into clinically relevant compounds, with multiple candidates advancing to clinical trials. The publications span medicinal chemistry, pharmacology, and clinical research, reflecting his interdisciplinary approach to drug discovery.

• P1 Teacher of the Year, Roseman University of Health Sciences (2018-2019)
• Thomas A. Edison Patent Award, Research and Development Council of New Jersey (2017)
• Sigma Xi Outstanding Thesis, Brigham Young University (1990)
• NSF Predoctoral Fellowship, Honorable Mention (1988)
• Trustee's Scholarship, Brigham Young University (1982-1987)

Dr. Rawlins has successfully guided multiple compounds into clinical development during his industry career, including an LIMK2 inhibitor for glaucoma, sotagliflozin (a dual SGLT1/SGLT2 inhibitor), and LX2761. His research has been supported by both industry resources during his pharmaceutical career and academic funding in his current position. He has mentored students through his teaching roles in Biochemistry, Pharmacogenomics, Medicinal Chemistry, Pharmaceutical Calculations, and Medical Spanish.

At Roseman University, Dr. Rawlins leads research efforts focused on novel antidepressant development, essential oil characterization, and 3D printing applications for drug delivery. His cheminformatics expertise informs both his research and his development of educational tools for pharmacy students. His laboratory work bridges synthetic organic chemistry with pharmaceutical applications, maintaining strong connections to his industry drug discovery experience.